Cell surface heparan sulfate proteoglycans influence MHC class II-restricted antigen presentation

Journal of Immunology

Volumn 185, Issue 7, 2010, Pages 3847-3856

  Léonetti, Michel ^a   Gadzinski, Adeline ^a   Moine, Gervaise ^a  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEOHEPARAN SULFATE; TRANSACTIVATOR PROTEIN; HLA ANTIGEN CLASS 2;

ANIMAL CELL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL SURFACE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; B LYMPHOCYTE; CELL MEMBRANE; CHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; CELL MEMBRANE; HEPARAN SULFATE PROTEOGLYCANS; HISTOCOMPATIBILITY ANTIGENS CLASS II; LYMPHOCYTE ACTIVATION; MICE; T-LYMPHOCYTES;

EID: 77958138601     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902724     Document Type: Article

References (44)

1. Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182:389-400.
2. Lanzavecchia, A. 1996. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol. 8:348-354.
3. Watts, C. 1997. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 15:821-850.
4. Théry, C., and S. Amigorena. 2001. The cell biology of antigen presentation in dendritic cells. Curr. Opin. Immunol. 13:45-51.
5. Guermonprez, P., J. Valladeau, L. Zitvogel, C. Théry, and S. Amigorena. 2002. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20:621-667.
6. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118.
7. Park, P. W., O. Reizes, and M. Bernfield. 2000. Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. J. Biol. Chem. 275:29923-29926.
8. Wadström, T., and A. Ljungh. 1999. Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: key events in microbial pathogenicity. J. Med. Microbiol. 48:223-233.
9. Menozzi, F. D., K. Pethe, P. Bifani, F. Soncin, M. J. Brennan, and C. Locht. 2002. Enhanced bacterial virulence through exploitation of host glycosaminoglycans. Mol. Microbiol. 43:1379-1386.
10. Patel, M., M. Yanagishita, G. Roderiquez, D. C. Bou-Habib, T. Oravecz, V. C. Hascall, and M. A. Norcross. 1993. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum. Retroviruses 9:167-174.
11. Roderiquez, G., T. Oravecz, M. Yanagishita, D. C. Bou-Habib, H. Mostowski, and M. A. Norcross. 1995. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J. Virol. 69:2233-2239.
12. Compton, T., D. M. Nowlin, and N. R. Cooper. 1993. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 193:834-841.
13. Butcher, B. A., L. A. Sklar, L. C. Seamer, and R. H. Glew. 1992. Heparin enhances the interaction of infective Leishmania donovani promastigotes with mouse peritoneal macrophages. A fluorescence flow cytometric analysis. J. Immunol. 148:2879-2886.
14. Love, D. C., J. D. Esko, and D. M. Mosser. 1993. A heparin-binding activity on Leishmania amastigotes which mediates adhesion to cellular proteoglycans. J. Cell Biol. 123:759-766.
15. Gleizes, P. E., J. Noaillac-Depeyre, F. Amalric, and N. Gas. 1995. Basic fibroblast growth factor (FGF-2) internalization through the heparan sulfate proteoglycansmediated pathway: an ultrastructural approach. Eur. J. Cell Biol. 66:47-59.
16. Gleizes, P. E., J. Noaillac-Depeyre, M. A. Dupont, and N. Gas. 1996. Basic fibroblast growth factor (FGF-2) is addressed to caveolae after binding to the plasma membrane of BHK cells. Eur. J. Cell Biol. 71:144-153.
17. Conrad, H. E. 1998. Heparin-Binding Proteins, Vol. 1. Academic Press, San Diego, CA.
18. Carey, D. J. 1997. Syndecans: multifunctional cell-surface co-receptors. Biochem. J. 327:1-16.
19. Léonetti, M., L. Pillet, B. Maillère, H. Lamthanh, P. Frachon, J. Couderc, and A. Ménez. 1990. Immunization with a peptide having both T cell and conformationally restricted B cell epitopes elicits neutralizing antisera against a snake neurotoxin. J. Immunol. 145:4214-4221.
20. Maillère, B., J. Cotton, G. Mourier, M. Léonetti, S. Leroy, and A. Ménez. 1993. Role of thiols in the presentation of a snake toxin to murine T cells. J. Immunol. 150:5270-5280.
21. Thai, R., G. Moine, M. Desmadril, D. Servent, J. L. Tarride, A. Ménez, and M. Léonetti. 2004. Antigen stability controls antigen presentation. J. Biol. Chem. 279:50257-50266.
22. Albini, A., R. Benelli, M. Presta, M. Rusnati, M. Ziche, A. Rubartelli, G. Paglialunga, F. Bussolino, and D. Noonan. 1996. HIV-tat protein is a heparinbinding angiogenic growth factor. Oncogene 12:289-297.
23. Rusnati, M., D. Coltrini, P. Oreste, G. Zoppetti, A. Albini, D. Noonan, F. d'Adda di Fagagna, M. Giacca, and M. Presta. 1997. Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J. Biol. Chem. 272:11313-11320.
24. Chang, H. C., F. Samaniego, B. C. Nair, L. Buonaguro, and B. Ensoli. 1997. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11:1421-1431.
25. Tyagi, M., M. Rusnati, M. Presta, and M. Giacca. 2001. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276:3254-3261.
26. Patel, H. V., A. A. Vyas, K. A. Vyas, Y. S. Liu, C. M. Chiang, L. M. Chi, and W. Wu. 1997. Heparin and heparan sulfate bind to snake cardiotoxin. Sulfated oligosaccharidesasapotential target for cardiotoxin action. J. Biol. Chem. 272:1484-1492.
27. Léonetti, M., J. Galon, R. Thai, C. Sautès-Fridman, G. Moine, and A. Ménez. 1999. Presentation of antigen in immune complexes is boosted by soluble bacterial immunoglobulin binding proteins. J. Exp. Med. 189:1217-1228.
28. Kittiworakarn, J., A. Lecoq, G. Moine, R. Thai, E. Lajeunesse, P. Drevet, C. Vidaud, A. Ménez, and M. Léonetti. 2006. HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers. J. Biol. Chem. 281:3105-3115.
29. Kessler, P., F. Kotzyba-Hibert, M. Leonetti, F. Bouet, P. Ringler, A. Brisson, A. Ménez, M. P. Goeldner, and C. Hirth. 1994. Synthesis of an acetylcholine receptor-specific toxin derivative regioselectively labeled with an undecagold cluster. Bioconjug. Chem. 5:199-204.
30. Maillère, B., G. Mourier, J. Cotton, M. Hervé, S. Leroy, and A. Ménez. 1995. Probing immunogenicity of a T cell epitope by L-alanine and D-amino acidscanning. Mol. Immunol. 32:1073-1080.
31. Amigorena, S., C. Bonnerot, J. R. Drake, D. Choquet, W. Hunziker, J. G. Guillet, P. Webster, C. Sautes, I. Mellman, and W. H. Fridman. 1992. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 256:1808-1812.
32. Amigorena, S., D. Lankar, V. Briken, L. Gapin, M. Viguier, and C. Bonnerot. 1998. Type II and III receptors for immunoglobulin G (IgG) control the presentation of different T cell epitopes from single IgG-complexed antigens. J. Exp. Med. 187:505-515.
33. Regnault, A., D. Lankar, V. Lacabanne, A. Rodriguez, C. Théry, M. Rescigno, T. Saito, S. Verbeek, C. Bonnerot, P. Ricciardi-Castagnoli, and S. Amigorena. 1999. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:371-380.
34. Miller, J., J. A. Hatch, S. Simonis, and S. E. Cullen. 1988. Identification of the glycosaminoglycan-attachment site of mouse invariant-chain proteoglycan core protein by site-directed mutagenesis. Proc. Natl. Acad. Sci. USA 85:1369.
35. Naujokas, M. F., M. Morin, M. S. Anderson, M. Peterson, and J. Miller. 1993. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 74:257-268.
36. Arunachalam, B., U. T. Phan, H. J. Geuze, and P. Cresswell. 2000. Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gammainterferon-inducible lysosomal thiol reductase (GILT). Proc. Natl. Acad. Sci. USA 97:745-750.
37. Maric, M., B. Arunachalam, U. T. Phan, C. Dong, W. S. Garrett, K. S. Cannon, C. Alfonso, L. Karlsson, R. A. Flavell, and P. Cresswell. 2001. Defective antigen processing in GILT-free mice. Science 294:1361-1365.
38. Mitsui, H., T. Inozume, R. Kitamura, N. Shibagaki, and S. Shimada. 2006. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. J. Invest. Dermatol. 126:1804-1812.
39. Fittipaldi, A., A. Ferrari, M. Zoppé, C. Arcangeli, V. Pellegrini, F. Beltram, and M. Giacca. 2003. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem. 278:34141-34149.
40. Futaki, S. 2006. Oligoarginine vectors for intracellular delivery: design and cellularuptake mechanisms. Biopolymers 84:241-249.
41. Weaver, J. M., C. A. Lazarski, K. A. Richards, F. A. Chaves, S. A. Jenks, P. R. Menges, and A. J. Sant. 2008. Immunodominance of CD4T cellstoforeign antigens ispeptide intrinsic and independent of molecular context: implications for vaccine design. J. Immunol. 181:3039-3048.
42. Delamarre, L., M. Pack, H. Chang, I. Mellman, and E. S. Trombetta. 2005. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307:1630-1634.
43. Wegrowski, Y., A. L. Milard, G. Kotlarz, E. Toulmonde, F. X. Maquart, and J. Bernard. 2006. Cell surface proteoglycan expression during maturation of human monocytesderived dendritic cells and macrophages. Clin. Exp. Immunol. 144:485-493.
44. Imberty, A., H. Lortat-Jacob, and S. Pérez. 2007. Structural view of glycosaminoglycan-protein interactions. Carbohydr. Res. 342:430-439.